23andMe Investor Day Presentation Deck
Using PheWAS to Identify Immuno-oncology Targets
We have defined an 'immuno-oncology signature'; genetic evidence that a particular gene both activates
the immune system and simultaneously reduces cancer risk.
Immune and
autoimmune
phenotypes
Cancer
phenotypes
Identified novel immuno-oncology
signature around CTLA4.
tonsillectomy
anti_tnf_alpha_or_dmards
t1d-
signed log(p)
juvenile_t1d-
iqb.dry_skin_frequency -
iodine treatment_ever-
hypothyroidism -
hyperthyroidism -
hashimotos-
graves -
vitiligo -
iqb.dandruff_frequency -
celiac HLA_all-
psoriasis
rheumatoid arthritis -
took_meds_anti_tnf_alpha-
thyroid_removed -
immunodeficiency-
squamous_cell_carcinoma -
basal cell carcinoma -
actinic_keratosis
non_melanoma_skin_cancer-
any_skin_cancer-
-10 -5 0 5 10
Genetic Variant in CTLA4
linked with multiple phenotypes
in the 23andMe database
Gene
IO
signature?
1
Use machine learning (ML) techniques to scan the genome and
identify genes with similar signatures.
X
2
X
3
➡X
4
5
6
Similarity classifier
7
➡X
➡X
8
➡X
9
X
Copyright © 2022 23andMe, Inc. 23andMe® 32View entire presentation